The administration of Lactobacillus rhamnosus to NAFLD mice for 8 weeks increases the abundance of beneficial bacteria in the distal small intestine and decreases portal alanine aminotransferase activity, thereby reducing the symptoms of NAFLD [91]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.